New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
July 29, 2014
06:57 EDTZFGNZafgen initiated with an Outperform at JMP Securities
Target $31.
News For ZFGN From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
May 28, 2015
07:15 EDTZFGNZafgen completes enrollment of U.S. Phase 3 trial of Beloranib
Zafgen announced that the company has completed enrollment of ZAF-311, also known as the Beloranib Efficacy Safety and Tolerability in Prader-Willi syndrome study, a Phase 3 clinical trial of beloranib for the treatment of patients with Prader-Willi syndrome. The objective of the study is to evaluate the efficacy and safety of beloranib in PWS patients over 6 months of randomized treatment, followed by a six-month open label extension. The trial includes 108 patients with PWS enrolled across 15 sites in the U.S.; the planned enrollment target number was 102 patients. Thomas Hughes, Ph.D., CEO of Zafgen, said, "We remain committed to advancing beloranib and further exploring its potential as an effective treatment option for patients and families living with this challenging condition. We expect the first data readout from this trial early in the first quarter next year."

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use